RegulatoryCompany release
FDA approves Roche's oral SERD Wilserdly with everolimus for ESR1-mutated breast cancer
F. Hoffmann-La Roche Ltd · Mon 16 Nov 2026
Roche says the US regulator has cleared giredestrant plus everolimus for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after prior endocrine therapy.
Roche announced on 16 November 2026 that the US Food and Drug Administration has approved Wilserdly (giredestrant), an oral selective oestrogen receptor degrader (SERD), for use in combination with everolimus.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release: F. Hoffmann-La Roche Ltd ↗
Article written by VigiEye from the official source (F. Hoffmann-La Roche Ltd). Claims are the company's own. AI-assisted; check the source before acting.
More Regulatory
All →
FDA approves Roche's Wilserdly with everolimus for ESR1-mutated advanced breast cancer
Roche · Mon 16 Nov 2026
AEON Biopharma gets FDA Type 2b feedback on ABP-450 biosimilar route to BOTOX
🇺🇸 AEON Biopharma, Inc. (AEON) · Mon 16 Nov 2026
iMDx Pauses FDA De Novo Review of GraftAssureDx Kidney Rejection Test, Plans January Response
🇺🇸 Insight Molecular Diagnostics Inc. (IMDX) · Mon 16 Nov 2026
Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission
🇺🇸 Cumberland Pharmaceuticals Inc (CPIX) · Mon 16 Nov 2026
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026